Table 1.
Characteristics of HGSOC patients by NLR.
| Total | Group 1 (NLR ≤ 4) | Group 2 (NLR > 4) | P-value | |
|---|---|---|---|---|
| N (%) | N (%) | N (%) | ||
| All cases | 397 | 196 (49.4) | 201 (50.6) | |
| Mean age at diagnosis (range, years) | 60.2 (27–89) | 60.8 (27–89) | 59.8 (30–85) | 0.837 |
| Type of BRCA mutation | 0.97 | |||
| No mutation | 271 (68.3) | 135 (68.3) | 136 (68.3) | |
| BRCA1 | 79 (19.9) | 39 (20.1) | 40 (20.1) | |
| BRCA2 | 47 (11.8) | 24 (12.1) | 23 (11.6) | |
| CA125, mean (SD), UI/mL | 2632 (4265) | 2085 (3152) | 1973 (3190) | 0.81 |
| FIGO stage at diagnosisa | ||||
| III | 282 (71.8) | 144 (73.1) | 138 (70.4) | 0.31 |
| IV | 111 (28.2) | 53 (26.9) | 58 (29.6) | |
| LPS-PIVb | ||||
| < 8 | 173 (43.9) | 108 (55.4) | 65 (32.7) | 0.0001 |
| ≥ 8 | 221 (56.1) | 87 (44.6) | 134 (67.3) | |
| Primary treatment strategy | ||||
| PDS | 186 (46.9) | 110 (55.6) | 76 (38.2) | 0.001 |
| NACT | 211 (53.1) | 88 (44.4) | 123 (61.8) | |
| Surgical complexity scorec,* | ||||
| 1–2 | 82 (44.6) | 59 (54.1) | 23 (30.7) | 0.002 |
| 3 | 102 (55.4) | 50 (45.9) | 52 (69.3) | |
| RT at primary surgery (PDS) | ||||
| 0 | 158 (84.9) | 92 (83.6) | 66 (86.8) | 0.75 |
| 1–10 mm | 18 (9.7) | 11 (10) | 7 (9.1) | |
| > 1 cm | 10 (5.4) | 7 (6.4) | 3 (3.9) | |
WT: wild type; VUS: variants of uncertain significance; PVs: pathogenetic variants; FIGO: International Federation of Gynecology and Obstetrics; LPS-PIV: laparoscopic predictive index value; PDS: primary debulking surgery; NACT: neoadjuvant chemotherapy; RT residual tumor; NLR: neutrophile/lymphocyte ratio.
aData calculated on 393 patients due to lack of data of 4 patients.
bData calculated on 394 patients due to lack of data of 3 patients.
cData calculated on 395 patients due to lack of data of 2 patients.
* Calculated only in women treated with PDS.